To include your compound in the COVID-19 Resource Center, submit it here.

Hirulog thrombin inhibitor data

BGEN (Cambridge, Mass.) presented results of two Phase II trials, totalling 4,088 evaluable patients, showing the agent to be safer than heparin but not much

Read the full 253 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE